Lantern Pharma Reveals Promising Preclinical Results for Pediatric Brain Cancer Treatment
TL;DR
Lantern Pharma's LP-184 shows promising results in improving survival rates for pediatric brain cancer, potentially revolutionizing treatment.
LP-184 by Lantern Pharma demonstrated significant anti-tumor activity in ATRT subtypes with high blood-brain barrier penetration and a safe profile.
Lantern Pharma's research on LP-184 for pediatric brain cancer offers hope for effective, low-toxicity treatments, aiming to enhance patient outcomes.
LP-184's success in improving survival rates for pediatric brain cancer highlights a potential breakthrough in cancer treatment with promising implications.
Found this article helpful?
Share it with your network and spread the knowledge!
Pharmaceutical company Lantern Pharma has reported significant preclinical success with its experimental drug LP-184 in treating atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive form of pediatric brain cancer. Research presented at the Society for Neuro-Oncology's Pediatric Neuro-Oncology Conference revealed promising results that could potentially transform treatment approaches for this challenging disease.
Dr. Eric Raabe from Johns Hopkins University shared data demonstrating LP-184's remarkable potential. In two mouse models, the drug showed substantial improvements in survival rates, with one model experiencing a dramatic 345% increase in median survival—extending from 20 to 89 days, with statistical significance (p<0.0001).
The research highlighted LP-184's key strengths, including potent anti-tumor activity across ATRT subtypes, excellent blood-brain barrier penetration, and a favorable safety profile. These characteristics are particularly important given that ATRT, driven by SMARCB1 gene inactivation, currently lacks effective, low-toxicity treatment options.
Lantern Pharma plans to advance LP-184 into clinical trials, with a pediatric Phase I trial targeted for late 2025 or early 2026. This timeline follows the completion of an ongoing adult trial and is contingent upon consortium approvals. The potential development represents a significant step forward in addressing a critical unmet medical need in pediatric oncology.
The findings underscore the company's AI-driven approach to drug discovery, leveraging machine learning technologies to accelerate oncology research and develop innovative therapeutic candidates. By utilizing their RADR® platform, which analyzes over 200 billion oncology-focused data points, Lantern Pharma continues to push the boundaries of cancer treatment research.
Curated from InvestorBrandNetwork (IBN)
